This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Epione Medical Corporation
On January 9, 2013 the 10-month court injunction on Botox competitor Xeomin expired. Simon Ourian, M.D. of Epione Beverly Hills says that competition is good for the industry and consumers alike.
Los Angeles, CA (PRWEB) January 20, 2013
“I don’t see how this can be anything but a good thing for consumers,” opines Dr. Ourian, Medical Director of Epione Beverly Hills. “First there was Botox, then Dysport and now Xeomin, each with certain distinct attributes. This can only enable me to do a better job of serving the needs of my patients.”
The injunction, issued by a U.S. District Judge on March 9, 2012, prevented Merz USA from doing a full commercial launch of Xeomin, the wrinkle-busting drug it developed to compete against market leader Allergan’s Botox. The judge concluded that several salespeople hired away from Allergan by Merz took confidential client information and market research when they left. (go to: goo.gl/IvkbK)
“Regardless of which treatment option you choose, consumers need to be smart and safe about the doctor they choose,” says Dr. Ourian. “That why I recently created a six-point Botox checklist.”
For more information about Botox Competitor Cleared to Re-Enter the Market click here.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10340972.htm